• Rosen Law Firm is investigating potential securities claims on behalf of Tandem Diabetes Care shareholders after the company previously issued a voluntary medical device correction for select t:slim X2 insulin pumps due to a potential speaker-related issue that could stop insulin delivery.
• This combination of a product correction involving life-sustaining insulin pumps and a securities-focused law firm investigation raises important questions about Tandem Diabetes Care’s risk controls, disclosure practices, and exposure to future legal or regulatory scrutiny.
• We’ll now examine how the device correction and related securities investigation could influence Tandem Diabetes Care’s broader investment narrative.

The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

What Is Tandem Diabetes Care's Investment Narrative?

For Tandem Diabetes Care, the core investment story still hinges on whether you believe its pump and automated insulin delivery ecosystem can convert clinical progress into a sustainable, profitable business. The product pipeline around Control IQ+, expanded type 2 labeling and the Mobi and CGM integrations positions the company in attractive parts of the diabetes technology market, but recent results and guidance underline that it is still loss making and growing at a measured pace. Against that backdrop, the t:slim X2 device correction and Rosen Law Firm securities investigation add a sharper edge to near term catalysts and risks. Q4 2025 results and any commentary on safety, legal exposure and potential regulatory follow up now matter more for assessing both confidence in management and how much room Tandem has to keep investing in growth.

However, there is a separate risk around how potential legal or regulatory outcomes could affect future reinvestment capacity that investors should be aware of. Despite retreating, Tandem Diabetes Care's shares might still be trading 7% above their fair value. Discover the potential downside here.

Exploring Other Perspectives

Five fair value estimates from the Simply Wall St Community span roughly US$22 to above US$51 per share, showing how differently private investors see Tandem’s upside. Set against recent device and legal uncertainty, this spread underlines why many market participants are reassessing what level of risk they are comfortable owning here.

Explore 5 other fair value estimates on Tandem Diabetes Care - why the stock might be worth just $22.33!

Build Your Own Tandem Diabetes Care Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Tandem Diabetes Care research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Tandem Diabetes Care research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Tandem Diabetes Care's overall financial health at a glance.

Searching For A Fresh Perspective?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Find companies with promising cash flow potential yet trading below their fair value.
• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.
• These 10 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.